The Micronoma Team

Micronoma was founded by leaders in microbiome research with the goal of revolutionizing and advancing early cancer diagnostics and personalized treatment through sensitive microbiome techniques, ensuring that patients’ needs are identified and addressed by their clinicians at the earliest stage, for a better chance to live longer, healthier lives.


Sandrine Miller-Montgomery

President & CEO, Board Member

Sandrine Miller-Montgomery, Pharm.D., Ph.D., is the co-founder, Board member, President and CEO of Micronoma, the first cancer-detection company using microbial signals in liquid biopsy technology to detect and predict cancer at an early stage of the disease. Prior to this, she was executive director of UC San Diego’s Center for Microbiome Innovation (CMI) that she co-led with renowned microbiome researcher, Dr. Rob Knight. There, she established a world-class team focused on expanding industry and academic collaborations in the field of microbiome research that resulted in raising more than $40M of financial support through key partnerships toward application of this science to AI, diet and nutrition, aging, environment, human disease understanding and more. Before this, she had worked in large biotech and multinational companies in the life science industry, as well as start-ups. She has assumed different responsibilities from R&D director to leading sales and marketing organizations. She excels at preparing companies for successful exits as shown by her work at Helixis, acquired by Illumina, and MO BIO Labs acquired by QIAGEN. A scientist at heart and with a drive to bring life-changing innovation to the community, Sandrine has found her passion in leading Micronoma, committed, through its early stage diagnosis, to improving the lives of all affected by cancer.

Greg Poore

Chief Analytics Officer, Board Member

Greg Sepich-Poore, Ph.D., and MD candidate, is the co-founder and chief analytics officer (CAO) of Micronoma and the co-inventor of patent pending Oncobiota™, its method to diagnose cancer using microbial nucleic acids.  As the CAO, he uses his expertise in microbiome science and machine learning methodologies to guide the company’s strategy for translating copious amounts of cell-free microbiome data into patient diagnoses. At only age 28, Micronoma is Greg’s third corporation and was strongly inspired by the unexpected stage IV diagnosis and tragic sudden loss of his grandmother to pancreatic cancer while attending college.

Greg has co-authored peer-reviewed papers in high-impact journals, including Nature, Science, Cell, and Nature Genetics, is inventor on multiple filed patents and was awarded NIH fellowship funding for his research on the cancer microbiome (F30, 2019-Present). Working at the nexus of medicine, science, and entrepreneurship it is his overall goal to develop innovative and translational technologies that improve the diagnosis, management, and treatment of chronic diseases.

Greg is a passionate entrepreneur with a heart to help others. He founded his first non-profit corporation at age 18 to provide educational opportunities to underprivileged and foster youth in south Florida, and then co-founded his first med tech company, Vigor Medical Systems, at age 22 to help his friends better manage their asthma conditions.

Rob Knight

Scientific Advisory Board

Rob Knight, Ph.D., is the co-founder of Micronoma and co-inventor of the patent pending Oncobiota™ method/platform.  He also serves on Micronoma’s Scientific Advisory Board. He is the founding director of the Center for Microbiome Innovation (CMI) and Professor of Pediatrics and Computer Science & Engineering at UC San Diego. Before that, he was Professor of Chemistry & Biochemistry and Computer Science in the BioFrontiers Institute of the University of Colorado at Boulder, and an HHMI Early Career Scientist. He is a fellow of the American Association for the Advancement of Science and of the American Academy of Microbiology. He was honored with the 2019 NIH Director’s Pioneer Award for his microbiome research. He received the 2017 Massry Prize, often considered a predictor of the Nobel Prize. In 2015 he received the Vilcek Prize in Creative Promise for the Life Sciences. He is the author of “Follow Your Gut: The Enormous Impact of Tiny Microbes” (Simon & Schuster, 2015), coauthor of “Dirt is Good: The Advantage of Germs for Your Child’s Developing Immune System” (St. Martin’s Press, 2017). His TED talk presentation in 2014 was viewed more than 2 million times. His lab has produced many of the software tools and laboratory techniques that enabled high-throughput microbiome science, including the QIIME pipeline (cited over 30,000 times as of this writing) and UniFrac (cited over 8,000 times). He is co-founder of the Earth Microbiome Project and the American Gut Project. In addition to his work with microbiome and early-cancer detection, his work has linked microbes to a range of health conditions including obesity and inflammatory bowel disease, has enhanced our understanding of microbes in environments ranging from the oceans to the tundra, and made high-throughput sequencing techniques accessible to thousands of researchers around the world.

Board of Directors (5)

Chidozie Ugwumba

Symbiosis VC

Magda Marquet, Ph.D.

Chairman of the BOD, independant member


Wesley Winn

Symbiosis VC

Sandrine Miller-Montgomery, President and CEO, and Greg Poore, CAO


Sandrine Miller-Montgomery, Pharm.D, Ph.D.

President & CEO, Board Member

Greg Poore, Ph.D.

Chief Analytics Officer, Board Member

Eddie Adams, Ph.D.

Chief Scientific Officer

Darryl Garrison

Chief Operating Officer

Todd Czerwinski

Todd Czerwinski

Vice President of Business Development

Scientific Advisory Board

Martin J. Blaser, M.D.

Chairman, Professor of Medicine and Pathology and Director of the Center for Advanced Biotechnology and Medicine, and holds the Henry Rutgers Chair of the Human Microbiome at Rutgers University.

Leena Das-Young, Pharm. D.

C-suite executive for biopharma in oncology, infectious disease, liquid biopsy, and product development in complex disease and precision medicine settings, including executive roles at both Pfizer and Guardant Health.

Ravid Straussman, M.D., Ph.D.

Principal Investigator at the Weizmann Institute where his research is focused on understanding the roles of the tumor microenvironment and the tumor microbiome on resistance to cytotoxic, targeted, and immune-mediated anti-cancer therapies.

Jennifer Wargo, M.D., M.M.Sc.

Professor, Surgical Oncology & Genomic Medicine at The University of Texas MD Anderson Cancer Center in Houston. Dr. Wargo has led and published key research on the microbiome and the role it plays in patient response to cancer therapy.

Research Partners

Micronoma is proud to partner with many internationally recognized academic institutions and non-for profit entities. Together, we are uniquely poised to revolutionize early-stage cancer detection, and along with it, significantly improve patients’ lives.


Contact Us

If you have questions or would like to learn more, please email us at or learn about joining our team at Careers.

6342 Ferris Square
San Diego, CA 92121